Literature DB >> 21272201

Is there an increased cancer risk associated with the use of angiotensin receptor blockers and should it affect current prescribing?

Debbie L Cohen1, Raymond R Townsend.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21272201      PMCID： PMC8673182          DOI： 10.1111/j.1751-7176.2010.00403.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  12 in total

Review 1.  Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials.

Authors:  Ilke Sipahi; Sara M Debanne; Douglas Y Rowland; Daniel I Simon; James C Fang
Journal:  Lancet Oncol       Date:  2010-06-11       Impact factor: 41.316

Review 2.  Is the use of some calcium antagonists linked to cancer? Evidence from recent observational studies.

Authors:  M Pahor; C D Furberg
Journal:  Drugs Aging       Date:  1998-08       Impact factor: 3.923

3.  Use of calcium channel blockers and breast carcinoma risk in postmenopausal women.

Authors:  A L Fitzpatrick; J R Daling; C D Furberg; R A Kronmal; J L Weissfeld
Journal:  Cancer       Date:  1997-10-15       Impact factor: 6.860

Review 4.  Carcinogenicity of antihypertensive therapy.

Authors:  Ehud Grossman; Franz H Messerli; Uri Goldbourt
Journal:  Curr Hypertens Rep       Date:  2002-06       Impact factor: 5.369

5.  Retrospective study of the association between use of rauwolfia derivatives and breast cancer in English women.

Authors:  B Armstrong; N Stevens; R Doll
Journal:  Lancet       Date:  1974-09-21       Impact factor: 79.321

Review 6.  Does diuretic therapy increase the risk of renal cell carcinoma?

Authors:  E Grossman; F H Messerli; U Goldbourt
Journal:  Am J Cardiol       Date:  1999-04-01       Impact factor: 2.778

7.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

Review 8.  Angiotensin receptors: a new role in cancer?

Authors:  Frédérique Deshayes; Clara Nahmias
Journal:  Trends Endocrinol Metab       Date:  2005-09       Impact factor: 12.015

9.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.

Authors:  Marc A Pfeffer; Karl Swedberg; Christopher B Granger; Peter Held; John J V McMurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren; Salim Yusuf; Stuart Pocock
Journal:  Lancet       Date:  2003-09-06       Impact factor: 79.321

10.  Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.

Authors:  S Yusuf; K Teo; C Anderson; J Pogue; L Dyal; I Copland; H Schumacher; G Dagenais; P Sleight
Journal:  Lancet       Date:  2008-08-29       Impact factor: 79.321
View more
  1 in total

1.  Angiotensin and systems thinking: wrapping your mind around the big picture.

Authors:  Gary Robert Smith
Journal:  Ochsner J       Date:  2013
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.